Physician profile
Dwight Keith Carson
NPI 1417068776
$1,597.65
in general payments reported to CMS, 2019-2025
14 companies · $188 in 2025
The $188 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.82 · 2020: $38.27 · 2021: $207 · 2022: $569 · 2023: $291 · 2024: $286 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $765.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $568.72 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Abbvie INC. | $556.28 | 2021-2024 | Vraylar |
| Alkermes, INC. | $122.82 | 2020-2023 | Vivitrol |
| Baxter Healthcare | $78.62 | 2022 | |
| Hikma Pharmaceuticals USA | $49.89 | 2022 | |
| Uswm, LLC | $48.96 | 2023 | Lucemyra, Zimhi |
| Sunovion Pharmaceuticals INC. | $35.85 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.14 | 2025 | Caplyta |
| Orexo US, INC. | $24.71 | 2022 | |
| Braeburn INC. | $19.64 | 2023 | Brixadi |
| Teva Pharmaceuticals USA, INC. | $16.12 | 2023 | Austedo |
| Amgen INC. | $15.08 | 2024 | Repatha |
| Exact Sciences Corporation | $14.69 | 2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $14.13 | 2024 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dwight Carson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.